| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Apr―25 |
4-Octyl itaconate blocks STAT3-induced ACE2 expression to reduce uptake of SARS-CoV-2 |
Hauke J. Weiss, Alexander Hooftman, Clarisse Salgado-Benvindo, Robbert Boudewijns, Laurens Liesenborghs, Tristram A.J. Ryan, Demi van der Horst, Madalina E. Carter-Timofte, Hossam Gewaid, Andrew Bowie, Hendrik Jan Thibaut, Kai Dallmeier, David Olagnier, Martijn J. van Hemert, Luke A.J. O’Neill |
| 2 |
[GO] |
2026―Feb―17 |
From 2020 to 2025: Comprehensive review Decoding novel structural inhibitors for Mpro of SARS-CoV-2 |
Xin Zhang, Yuxin Xu, Yunzhi Jiang, Junjie Huang, Xiaolin Li |
| 3 |
[GO] |
2025―Jan―17 |
Corrigendum to “Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin” [Biochem. Pharmacol. 215 (2023) 115688] |
Cheng-Wei Yang, Hsing-Yu Hsu, Yue-Zhi Lee, Jia-Tsrong Jan, Sui-Yuan Chang, Yi-Ling Lin, Ruey-Bing Yang, Tai-Ling Chao, Jian-Jong Liang, Shu-Jing Lin, Chun-Che Liao, Chih-Shin Chang, Huey-Kang Sytwu, Ming-Shiu Hung, Chiung-Tong Chen, Shiow-Ju Lee |
| 4 |
[GO] |
2024―Jun―22 |
Takotsubo syndrome as an outcome of the use of checkpoint inhibitor therapy in patients with COVID-19 |
Júlia Leão Batista Simões, Geórgia de Carvalho Braga, João Victor Coiado, Alexandre Bachietti Scaramussa, Ana Paula Barasuol Rodrigues, Margarete Dulce Bagatini |
| 5 |
[GO] |
2024―Feb―17 |
Developing CAR-immune cell therapy against SARS-COV-2: Current status, challenges, and prospects |
Yizhao Chen, Chong Liu, Yilong Fang, Weile Chen, Jiaqi Qiu, Mengjuan Zhu, Wei Wei, Jiajie Tu |
| 6 |
[GO] |
2023―Dec―09 |
Bile acids and bile acid activated receptors in the treatment of Covid-19 |
Stefano Fiorucci, Ginevra Urbani, Michele Biagioli, Valentina Sepe, Eleonora Distrutti, Angela Zampella |
| 7 |
[GO] |
2023―Jul―21 |
Natural fucoidans inhibit coronaviruses by targeting viral spike protein and host cell furin |
Cheng-Wei Yang, Hsing-Yu Hsu, Yue-Zhi Lee, Jia-Tsrong Jan, Sui-Yuan Chang, Yi-Ling Lin, Ruey-Bing Yang, Tai-Ling Chao, Jian-Jong Liang, Shu-Jing Lin, Chun-Che Liao, Chih-Shin Chang, Huey-Kang Sytwu, Ming-Shiu Hung, Chiung-Tong Chen, Shiow-Ju Lee |
| 8 |
[GO] |
2023―Jan―30 |
Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators |
Nusrath Yasmeen, S. Harikrishnan, Sudarshan S Lakhawat, Manali Datta, Pushpender K Sharma, Ajay Jain, Rakhi Khanna, S Jayalakshmi, Vikram Kumar |
| 9 |
[GO] |
2022―Dec―30 |
Applications of Nanobodies in the Prevention, Detection, and Treatment of the Evolving SARS-CoV-2 |
Wenyi Wang, Yue Hu, Bohan Li, Huanan Wang, Jinhua Shen |
| 10 |
[GO] |
2022―Dec―05 |
Counter-regulatory renin-angiotensin system in hypertension: review and update in the era of COVID-19 pandemic |
Hongyin Chen, Jiangyun Peng, Tengyao Wang, Jielu Wen, Sifan Chen, Yu Huang, Yang Zhang |
| 11 |
[GO] |
2022―Oct―31 |
Glycosylation in SARS-CoV-2 Variants: A path to Infection and Recovery |
Arya Aloor, Rajaguru Aradhya, Parvathy Venugopal, Bipin Gopalakrishnan Nair, Renuka Suravajhala |
| 12 |
[GO] |
2022―Oct―06 |
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges |
Xiaoying Xu, Yuheng Chen, Xinyu Lu, Wanlin Zhang, Wenxiu Fang, Luping Yuan, Xiaoyan Wang |
| 13 |
[GO] |
2022―Jul―03 |
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 |
Jin Huang, Chi Zhou, Jinniu Deng, Jianfeng Zhou |
| 14 |
[GO] |
2021―Nov―18 |
The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders |
Upasana Parthasarathy, Roberta Martinelli, Elisabeth H. Vollmann, Katharine Best, Alex G. Therien |
| 15 |
[GO] |
2021―Aug―08 |
Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2) |
Yusen Xiang, Mengge Wang, Hongzhuan Chen, Lili Chen |
| 16 |
[GO] |
2021―Apr―02 |
Animal Models for SARS-Cov2/Covid19 Research-A Commentary |
Kurt Jarnagin, Oscar Alvarez, Sujan Shresta, David R Webb |
| 17 |
[GO] |
2021―Feb―10 |
Sleep during COVID-19 lockdown: A cross-cultural study investigating job system relevance |
Cristina Florea, Pavlos Topalidis, Theresa Hauser, Monika Angerer, Anton Kurapov, Carlos Alberto Beltran Leon, Daniel Soares Brandão, Manuel Schabus |
| 18 |
[GO] |
2021―Jan―28 |
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking |
Claire Lugnier, Hayder M. AL-Kuraishi, Eric Rousseau |
| 19 |
[GO] |
2021―Jan―19 |
Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics |
Li Zeng, Dongying Li, Weida Tong, Tieliu Shi, Baitang Ning |
| 20 |
[GO] |
2020―Oct―27 |
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro |
Junke Song, Li Zhang, Yanfeng Xu, Dezhi Yang, Li Zhang, Shiying Yang, Wen Zhang, Jinhua Wang, Shuo Tian, Shengqian Yang, Tianyi Yuan, Ailin Liu, Qi Lu, Fengdi Li, Hongqi Liu, Biyu Hou, Xiaozhong Peng, Yang Lu, Guanhua Du |
| 21 |
[GO] |
2020―Oct―22 |
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action |
Hassan Yousefi, Ladan Mashouri, Samuel C. Okpechi, Nikhilesh Alahari, Suresh K. Alahari |
| 22 |
[GO] |
2020―Oct―04 |
Corrigendum to “Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost” [Biochem. Pharmacol. 178 (2020) 114057] |
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa |
| 23 |
[GO] |
2020―Sep―20 |
AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication |
Jonathan O. Rayner, Rosemary A. Roberts, Jin Kim, Andrew Poklepovic, Jane L. Roberts, Laurence Booth, Paul Dent |
| 24 |
[GO] |
2020―Sep―19 |
Role of Proteolytic Enzymes In the Covid-19 Infection And Promising Therapeutic Approaches |
Magda Gioia, Chiara Ciaccio, Paolo calligari, Giovanna De Simone, Diego sbardella, Grazia tundo, Giovanni Francesco Fasciglione, Alessandra di Masi, Donato Di Pierro, Alessio Bocedi, Paolo Ascenzi, Massimo Coletta |
| 25 |
[GO] |
2020―Sep―06 |
The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations |
Meik Neufurth, Xiaohong Wang, Emad Tolba, Ingo Lieberwirth, Shunfeng Wang, Heinz C. Schröder, Werner E.G. Müller |
| 26 |
[GO] |
2020―Jul―30 |
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials |
Rohan Chakraborty, Suhel Parvez |
| 27 |
[GO] |
2020―Jul―23 |
Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2 |
Lucia Lisi, Pedro Miguel Lacal, Maria Luisa Barbaccia, Grazia Graziani |
| 28 |
[GO] |
2020―Jun―25 |
Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction |
Gary Williamson, Asimina Kerimi |
| 29 |
[GO] |
2020―Jun―21 |
SARS-CoV-2 and Cardiovascular Complications: from Molecular Mechanisms to Pharmaceutical Management |
Lin Wu, Aislinn M. O'Kane, Hu Peng, Yaguang Bi, Dagmara Motriuk-Smith, Jun Ren |
| 30 |
[GO] |
2020―May―27 |
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost |
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa |
|
